{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:27:09Z","timestamp":1790634429990,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,11]],"date-time":"2021-02-11T00:00:00Z","timestamp":1613001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,11]],"date-time":"2021-02-11T00:00:00Z","timestamp":1613001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Proton pump inhibitors (PPIs) were widely used. Observational studies suggested increasing risk of kidney injury in patients with PPIs treatment. We gathered six PPI regimens and adverse reports of acute kidney injury (AKI) and chronic kidney disease (CKD) based on US FDA Adverse Event Reporting System (FAERS) database from 2004 to 2019. We employed reporting odds ratio (ROR) to detect signals. Finally, we identified 3187 PPIs-associated AKI cases and 3457 PPIs-associated CKD cases. We detected significant signals between PPIs and AKI as well as CKD. The signal strength was stronger for CKD (ROR\u2009=\u20098.80, 95% CI 8.49\u20139.13) than AKI (ROR\u2009=\u20093.95, 95% CI 3.81\u20134.10), while dexlansoprazole performed stronger association for CKD (ROR\u2009=\u200934.94, 95% CI 30.89\u201339.53) and AKI (ROR\u2009=\u20098.18, 95% CI 7.04\u20139.51) than the other five PPIs. The median time from PPIs use to event occurrence was 23\u00a0days for AKI and 177\u00a0days for CKD. PPIs-associated AKI resulted larger proportion of death, life-threatening, hospitalization and disability events than PPIs-associated CKD. By mining the FAERS big data, we provided more information between PPIs use and the AKI and CKD events. PPIs rational use should be repeatedly stressed.<\/jats:p>","DOI":"10.1038\/s41598-021-83099-y","type":"journal-article","created":{"date-parts":[[2021,2,11]],"date-time":"2021-02-11T11:03:58Z","timestamp":1613041438000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Proton pump inhibitors associated acute kidney injury and chronic kidney disease: data mining of US FDA adverse event reporting system"],"prefix":"10.1038","volume":"11","author":[{"given":"Bin","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyao","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuwen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,11]]},"reference":[{"key":"83099_CR1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.5009\/gnl15502","volume":"11","author":"DS Strand","year":"2017","unstructured":"Strand, D. S., Kim, D. & Peura, D. A. 25 years of proton pump inhibitors: A comprehensive review. Gut Liver 11, 27\u201337 (2017).","journal-title":"Gut Liver"},{"key":"83099_CR2","doi-asserted-by":"publisher","first-page":"738","DOI":"10.17235\/reed.2019.6155\/2019","volume":"111","author":"J Ying","year":"2019","unstructured":"Ying, J., Li, L. C., Wu, C. Y., Yu, Z. W. & Kan, L. D. The status of proton pump inhibitor use: A prescription survey of 45 hospitals in China. Rev. Esp. Enferm. Dig. 111, 738\u2013743 (2019).","journal-title":"Rev. Esp. Enferm. Dig."},{"key":"83099_CR3","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1002\/pds.4963","volume":"29","author":"L Pasina","year":"2020","unstructured":"Pasina, L., Novella, A., Elli, C., Nobili, A. & Ianes, A. Overuse of proton pump inhibitors in nursing homes: An Italian multicenter observational study. Pharmacoepidemiol. Drug Saf. 29, 461\u2013466 (2020).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"83099_CR4","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/bcpt.13023","volume":"123","author":"PF Haastrup","year":"2018","unstructured":"Haastrup, P. F., Thompson, W., S\u00f8ndergaard, J. & Jarb\u00f8l, D. E. Side effects of long-term proton pump inhibitor use: A review. Basic Clin. Pharmacol. Toxicol. 123, 114\u2013121 (2018).","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"83099_CR5","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.14428","author":"IE Perry","year":"2020","unstructured":"Perry, I. E. et al. Potential proton pump inhibitor-related adverse effects. Ann. N. Y. Acad. Sci. https:\/\/doi.org\/10.1111\/nyas.14428 (2020).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"83099_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvoice.2020.01.018","author":"A Rameau","year":"2020","unstructured":"Rameau, A., Andreadis, K., Bayoumi, A., Kaufman, M. & Belafsky, P. Side effects of proton pump inhibitors: What are patients\u2019 concerns? J. Voice. https:\/\/doi.org\/10.1016\/j.jvoice.2020.01.018 (2020).","journal-title":"J. Voice."},{"key":"83099_CR7","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.dld.2020.04.020","volume":"52","author":"V Savarino","year":"2020","unstructured":"Savarino, V. et al. Latest insights into the hot question of proton pump inhibitor safety-a narrative review. Dig. Liver Dis. 52, 842\u2013852 (2020).","journal-title":"Dig. Liver Dis."},{"key":"83099_CR8","doi-asserted-by":"publisher","first-page":"166","DOI":"10.9778\/cmajo.20140074","volume":"3","author":"T Antoniou","year":"2015","unstructured":"Antoniou, T. et al. Proton pump inhibitors and the risk of acute kidney injury in older patients: A population-based cohort study. CMAJ Open 3, 166\u2013171 (2015).","journal-title":"CMAJ Open"},{"key":"83099_CR9","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1002\/phar.2235","volume":"39","author":"E Hart","year":"2019","unstructured":"Hart, E., Dunn, T. E., Feuerstein, S. & Jacobs, D. M. Proton pump inhibitors and risk of acute and chronic kidney disease: A retrospective cohort study. Pharmacotherapy 39, 443\u2013453 (2019).","journal-title":"Pharmacotherapy"},{"key":"83099_CR10","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.2147\/DDDT.S130568","volume":"11","author":"Y Yang","year":"2017","unstructured":"Yang, Y. et al. Proton-pump inhibitors use, and risk of acute kidney injury: A meta-analysis of observational studies. Drug Des. Dev. Ther. 11, 1291\u20131299 (2017).","journal-title":"Drug Des. Dev. Ther."},{"key":"83099_CR11","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1093\/ndt\/gfw470","volume":"33","author":"S Nochaiwong","year":"2018","unstructured":"Nochaiwong, S. et al. The association between proton pump inhibitor use and the risk of adverse kidney outcomes: A systematic review and meta-analysis. Nephrol. Dial. Transplant. 33, 331\u2013342 (2018).","journal-title":"Nephrol. Dial. Transplant."},{"key":"83099_CR12","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1053\/j.gastro.2019.05.056","volume":"157","author":"P Moayyedi","year":"2019","unstructured":"Moayyedi, P. et al. Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin. Gastroenterology 157, 682\u2013691 (2019).","journal-title":"Gastroenterology"},{"key":"83099_CR13","unstructured":"FDA. Data Mining at FDA: White Paper (2018). https:\/\/www.fda.gov\/science-research\/data-mining\/data-mining-fda-white-paper. Accessed 1 May 2020."},{"key":"83099_CR14","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1093\/jamia\/ocv063","volume":"23","author":"HJ Duggirala","year":"2016","unstructured":"Duggirala, H. J. et al. Use of data mining at the Food and Drug Administration. J. Am. Med. Inform. Assoc. 23, 428\u2013434 (2016).","journal-title":"J. Am. Med. Inform. Assoc."},{"key":"83099_CR15","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJ Evans","year":"2001","unstructured":"Evans, S. J., Waller, P. C. & Davis, S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol. Drug Saf. 10, 483\u2013486 (2001).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"83099_CR16","doi-asserted-by":"publisher","first-page":"781","DOI":"10.2217\/cer-2019-0017","volume":"8","author":"SS Sutton","year":"2019","unstructured":"Sutton, S. S., Magagnoli, J., Cummings, T. H. & Hardin, J. W. Risk of acute kidney injury in patients with HIV receiving proton pump inhibitors. J. Comp. Eff. Res. 8, 781\u2013790 (2019).","journal-title":"J. Comp. Eff. Res."},{"key":"83099_CR17","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.15151","author":"G Chen","year":"2020","unstructured":"Chen, G. et al. Acute kidney injury following the use of different proton pump inhibitor regimens: A real-world analysis of post-marketing surveillance data. J. Gastroenterol. Hepatol. https:\/\/doi.org\/10.1111\/jgh.15151 (2020).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"83099_CR18","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1093\/qjmed\/hcz166","volume":"112","author":"CH Grant","year":"2019","unstructured":"Grant, C. H. et al. Proton pump inhibitor use and progression to major adverse renal events: A competing risk analysis. QJM 112, 835\u2013840 (2019).","journal-title":"QJM"},{"key":"83099_CR19","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.sapharm.2019.08.032","volume":"16","author":"R Devraj","year":"2020","unstructured":"Devraj, R. & Deshpande, M. Demographic and health-related predictors of proton pump inhibitor (PPI) use and association with chronic kidney disease (CKD) stage in NHANES population. Res. Soc. Admin. Pharm. 16, 776\u2013782 (2020).","journal-title":"Res. Soc. Admin. Pharm."},{"key":"83099_CR20","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1053\/j.gastro.2017.05.046","volume":"153","author":"DCF Klatte","year":"2017","unstructured":"Klatte, D. C. F. et al. Association between proton pump inhibitor use and risk of progression of chronic kidney disease. Gastroenterology 153, 702\u2013710 (2017).","journal-title":"Gastroenterology"},{"key":"83099_CR21","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1001\/jamainternmed.2015.7193","volume":"176","author":"B Lazarus","year":"2016","unstructured":"Lazarus, B. et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern. Med. 176, 238\u2013246 (2016).","journal-title":"JAMA Intern. Med."},{"key":"83099_CR22","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0140-6736(93)92531-W","volume":"341","author":"PB Christensen","year":"1993","unstructured":"Christensen, P. B., Albertsen, K. E. & Jensen, P. Renal failure after omeprazole. Lancet 341, 55 (1993).","journal-title":"Lancet"},{"key":"83099_CR23","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1002\/phar.2152","volume":"38","author":"HK Welch","year":"2018","unstructured":"Welch, H. K., Kellum, J. A. & Kane-Gill, S. L. Drug-associated acute kidney injury identified in the united states food and drug administration adverse event reporting system database. Pharmacother. J. Hum. Pharmacol. Drug Therapy 38, 785\u2013793 (2018).","journal-title":"Pharmacother. J. Hum. Pharmacol. Drug Therapy"},{"key":"83099_CR24","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1016\/j.kint.2016.12.021","volume":"91","author":"Y Xie","year":"2017","unstructured":"Xie, Y. et al. Long-term kidney outcomes among users of proton pump inhibitors without intervening acute kidney injury. Kidney Int. 91, 1482\u20131494 (2017).","journal-title":"Kidney Int."},{"key":"83099_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-016-0325-4","author":"P Arora","year":"2016","unstructured":"Arora, P. et al. Proton pump inhibitors are associated with increased risk of development of chronic kidney disease. BMC Nephrol. https:\/\/doi.org\/10.1186\/s12882-016-0325-4 (2016).","journal-title":"BMC Nephrol."},{"key":"83099_CR26","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1053\/j.ajkd.2019.07.012","volume":"75","author":"Z Al-Aly","year":"2020","unstructured":"Al-Aly, Z., Maddukuri, G. & Xie, Y. Proton pump inhibitors and the kidney: Implications of current evidence for clinical practice and when and how to deprescribe. Am. J. Kidney Dis. 75, 497\u2013500 (2020).","journal-title":"Am. J. Kidney Dis."},{"key":"83099_CR27","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s40265-019-01110-3","volume":"79","author":"E Elias","year":"2019","unstructured":"Elias, E. & Targownik, L. E. The clinician\u2019s guide to proton pump inhibitor related adverse events. Drugs 79, 715\u2013731 (2019).","journal-title":"Drugs"},{"key":"83099_CR28","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1097\/MOG.0000000000000641","volume":"36","author":"P Moayyedi","year":"2020","unstructured":"Moayyedi, P. How to advise patients on the risk of chronic proton pump inhibitor therapy. Curr. Opin. Gastroenterol. 36, 317\u2013322 (2020).","journal-title":"Curr. Opin. Gastroenterol."},{"key":"83099_CR29","doi-asserted-by":"publisher","first-page":"S66","DOI":"10.4103\/0976-500X.120955","volume":"4","author":"C Palleria","year":"2013","unstructured":"Palleria, C. et al. Limitations and obstacles of the spontaneous adverse drugs reactions reporting: Two \u201cchallenging\u201d case reports. J. Pharmacol. Pharmacother. 4, S66-72 (2013).","journal-title":"J. Pharmacol. Pharmacother."},{"key":"83099_CR30","unstructured":"FDA. FDA Adverse Event Reporting System (FAERS) Quarterly Data Extract Files (2019). https:\/\/fis.fda.gov\/extensions\/FPD-QDE-FAERS\/FPD-QDE-FAERS.html. Accessed 10 February 2020."},{"key":"83099_CR31","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1197\/jamia.M3378","volume":"17","author":"H Xu","year":"2010","unstructured":"Xu, H. et al. MedEx: A medication information extraction system for clinical narratives. J. Am. Med. Inform. Assoc. 17, 19\u201324 (2010).","journal-title":"J. Am. Med. Inform. Assoc."},{"key":"83099_CR32","first-page":"1989","volume":"39","author":"B Wu","year":"2019","unstructured":"Wu, B., Wu, F. B., Luo, M., Qin, Z. & Xu, T. Application of MedEx in FAERS drug names standardization. China J. Hosp Pharm. 39, 1989\u20131992 (2019).","journal-title":"China J. Hosp Pharm."},{"key":"83099_CR33","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","volume":"11","author":"EP van Puijenbroek","year":"2002","unstructured":"van Puijenbroek, E. P. et al. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol. Drug Saf. 11, 3\u201310 (2002).","journal-title":"Pharmacoepidemiol. Drug Saf."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-83099-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-83099-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-83099-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T03:39:30Z","timestamp":1670038770000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-83099-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,11]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["83099"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-83099-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,11]]},"assertion":[{"value":"18 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3690"}}